ES2881872T3 - Prevención o tratamiento de la hiperuricemia o de la gota - Google Patents
Prevención o tratamiento de la hiperuricemia o de la gota Download PDFInfo
- Publication number
- ES2881872T3 ES2881872T3 ES16742632T ES16742632T ES2881872T3 ES 2881872 T3 ES2881872 T3 ES 2881872T3 ES 16742632 T ES16742632 T ES 16742632T ES 16742632 T ES16742632 T ES 16742632T ES 2881872 T3 ES2881872 T3 ES 2881872T3
- Authority
- ES
- Spain
- Prior art keywords
- purine
- dione
- dihydro
- chloro
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CN(C(c1c(N2*)nc(*)[n]1)=O)C2=O Chemical compound CN(C(c1c(N2*)nc(*)[n]1)=O)C2=O 0.000 description 3
- WTUVPERXQXSPFE-UHFFFAOYSA-N CCCCCN(c1c(C(N2)=O)[n](CC=C)c(Cl)n1)C2=O Chemical compound CCCCCN(c1c(C(N2)=O)[n](CC=C)c(Cl)n1)C2=O WTUVPERXQXSPFE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510048096 | 2015-01-30 | ||
| CN201510080714 | 2015-02-13 | ||
| CN201510079809 | 2015-02-13 | ||
| CN201510216089 | 2015-04-30 | ||
| PCT/CN2016/000061 WO2016119570A1 (zh) | 2015-01-30 | 2016-01-28 | 尿酸性或痛风性疾病的预防或治疗 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2881872T3 true ES2881872T3 (es) | 2021-11-30 |
Family
ID=56542370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16742632T Active ES2881872T3 (es) | 2015-01-30 | 2016-01-28 | Prevención o tratamiento de la hiperuricemia o de la gota |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10322132B2 (ja) |
| EP (1) | EP3251675B1 (ja) |
| JP (1) | JP6678685B2 (ja) |
| KR (1) | KR102128810B1 (ja) |
| CN (1) | CN107206002B (ja) |
| AU (1) | AU2016212625B2 (ja) |
| BR (1) | BR112017016065A2 (ja) |
| CA (1) | CA2973746C (ja) |
| CY (1) | CY1124383T1 (ja) |
| DK (1) | DK3251675T3 (ja) |
| EA (1) | EA034139B1 (ja) |
| ES (1) | ES2881872T3 (ja) |
| HK (2) | HK1244434A1 (ja) |
| HR (1) | HRP20211007T1 (ja) |
| HU (1) | HUE054741T2 (ja) |
| IL (1) | IL253726B2 (ja) |
| LT (1) | LT3251675T (ja) |
| MA (1) | MA41431B1 (ja) |
| MX (1) | MX2017009853A (ja) |
| PL (1) | PL3251675T3 (ja) |
| PT (1) | PT3251675T (ja) |
| SG (2) | SG10201907026RA (ja) |
| SI (1) | SI3251675T1 (ja) |
| TW (1) | TWI680761B (ja) |
| WO (1) | WO2016119570A1 (ja) |
| ZA (1) | ZA201704600B (ja) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| WO1993016699A1 (en) | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | Tnf inhibitors |
| AR015966A1 (es) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
| CN101103030B (zh) | 2004-02-14 | 2010-10-13 | 史密丝克莱恩比彻姆公司 | 具有hm74a受体活性的药物 |
| ES2355325T3 (es) | 2006-06-23 | 2011-03-24 | Incyte Corporation | Derivados de purinona como agonistas de hm74a. |
| US7462624B2 (en) * | 2006-06-23 | 2008-12-09 | Incyte Corporation | Purinone derivatives as HM74a agonists |
| WO2010071865A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| US20110136835A1 (en) | 2009-09-14 | 2011-06-09 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
| WO2011057110A1 (en) | 2009-11-06 | 2011-05-12 | Ruprecht-Karls-Universitat-Heidelberg | Gpr109a agonists for the treatment of cerebral ischemia |
-
2016
- 2016-01-28 EA EA201791714A patent/EA034139B1/ru unknown
- 2016-01-28 PL PL16742632T patent/PL3251675T3/pl unknown
- 2016-01-28 SI SI201631264T patent/SI3251675T1/sl unknown
- 2016-01-28 PT PT167426329T patent/PT3251675T/pt unknown
- 2016-01-28 DK DK16742632.9T patent/DK3251675T3/da active
- 2016-01-28 MA MA41431A patent/MA41431B1/fr unknown
- 2016-01-28 MX MX2017009853A patent/MX2017009853A/es unknown
- 2016-01-28 ES ES16742632T patent/ES2881872T3/es active Active
- 2016-01-28 WO PCT/CN2016/000061 patent/WO2016119570A1/zh active Application Filing
- 2016-01-28 SG SG10201907026RA patent/SG10201907026RA/en unknown
- 2016-01-28 BR BR112017016065-0A patent/BR112017016065A2/pt not_active Application Discontinuation
- 2016-01-28 JP JP2017558605A patent/JP6678685B2/ja active Active
- 2016-01-28 CA CA2973746A patent/CA2973746C/en active Active
- 2016-01-28 LT LTEP16742632.9T patent/LT3251675T/lt unknown
- 2016-01-28 HU HUE16742632A patent/HUE054741T2/hu unknown
- 2016-01-28 US US15/512,412 patent/US10322132B2/en active Active
- 2016-01-28 KR KR1020177024392A patent/KR102128810B1/ko active IP Right Grant
- 2016-01-28 SG SG11201705889VA patent/SG11201705889VA/en unknown
- 2016-01-28 AU AU2016212625A patent/AU2016212625B2/en active Active
- 2016-01-28 CN CN201680001581.8A patent/CN107206002B/zh active Active
- 2016-01-28 EP EP16742632.9A patent/EP3251675B1/en active Active
- 2016-01-29 TW TW105102935A patent/TWI680761B/zh active
-
2017
- 2017-07-07 ZA ZA2017/04600A patent/ZA201704600B/en unknown
- 2017-07-30 IL IL253726A patent/IL253726B2/en unknown
-
2018
- 2018-03-21 HK HK18103914.7A patent/HK1244434A1/zh unknown
- 2018-04-16 HK HK18104884.1A patent/HK1245146A1/zh unknown
-
2021
- 2021-06-22 CY CY20211100551T patent/CY1124383T1/el unknown
- 2021-06-26 HR HRP20211007TT patent/HRP20211007T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022504601A (ja) | Ｍｓｔ１キナーゼ阻害剤及びその使用 | |
| WO2021135654A1 (zh) | 双硫仑在制备防治nlrp3炎症小体相关疾病的药物中的应用 | |
| WO2020177744A1 (zh) | 水杨酸类小檗碱型生物碱季铵盐及其制备药物的用途 | |
| US20170312273A1 (en) | Methods of using fasn inhibitors | |
| CN101250183A (zh) | 一种雷贝拉唑的光学异构体及其制备方法、医药用途 | |
| US20220401423A1 (en) | Methods for treating inflammatory bowel disease | |
| ES2881872T3 (es) | Prevención o tratamiento de la hiperuricemia o de la gota | |
| CN111093661B (zh) | 戊二酰亚胺衍生物用于治疗与细胞因子的异常活性相关的疾病的用途 | |
| JP2009073851A (ja) | ロキソプロフェン含有医薬製剤２ | |
| KR20080108156A (ko) | 유기 화합물의 조합물 | |
| WO2009041798A1 (es) | Composiciones farmacéuticas que comprenden la combinación de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa útiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas. | |
| US9962400B2 (en) | Methods and compositions for treating lupus | |
| KR20140003727A (ko) | 디프테로카르푸스 투베르쿨라투스 추출물을 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 조성물 | |
| KR20140137557A (ko) | 애엽과 전호의 추출 혼합물을 주성분으로 하는 염증성 질환 예방 및 치료용 치료용 천연물 조성물 | |
| TWI423800B (zh) | ４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於製備用於治療顱部創傷的藥物之用途 | |
| JP2008526945A (ja) | 抗炎症活性を有する９ａ−カルバモイルおよびチオカルバモイルアザライド | |
| KR101502392B1 (ko) | 이소에고마케톤을 포함하는 염증질환의 예방 또는 치료를 위한 경구투여용 약학 제형 | |
| KR20120012157A (ko) | 실로스타졸 또는 이의 약리학적 허용가능한 염을 유효성분으로 함유하는 패혈증 또는 패혈증성 쇼크 치료 및 예방용 약학조성물 | |
| WO2022121222A1 (zh) | 吡啶巯乙酸类化合物及其制备方法、药学衍生物或配剂以及应用 | |
| ES2666133T3 (es) | Derivado de protoescigenina, proceso de su preparación, uso de dicho compuesto y composición farmacéutica que comprende ese compuesto | |
| TW201022254A (en) | S1P lyase inhibitors for the treatment of cerebral malaria | |
| CN108863970A (zh) | 新化合物及其在治疗炎症或炎症相关疾病方面的应用 |